Tifuvirtide
Source Tifuvirtide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Tifuvirtide (also called T‑1249) is an experimental peptide designed to inhibit HIV‑1 entry by blocking the fusion step between the viral envelope and the host cell membrane. It belongs to the class of HIV‑1 fusion inhibitors and is being investigated as a potential addition to antiretroviral regimens, especially for viruses resistant to existing drugs. Early‑stage studies have placed it in clinical‑trial pipelines alongside other entry blockers.
Mechanism of Action
Tifuvirtide is a synthetic peptide that mimics a segment of the HIV‑1 gp41 heptad‑repeat 2 (HR2) region. By binding to the complementary HR1 region of gp41 during the conformational changes that follow CD4 and co‑receptor engagement, it prevents the formation of the six‑helix bundle required for merging the viral and cellular membranes, thereby halting entry of the virus into the target cell.
What the Research Shows
The peptide appears in two 2005 review articles that discuss emerging antiretroviral strategies. Both reviews list tifuvirtide (T‑1249) alongside enfuvirtide as a fusion inhibitor targeting the Env‑mediated membrane fusion step, and note that it has entered clinical‑trial evaluation as part of the expanding pipeline of entry inhibitors. A 2006 analytical study described a validated LC‑MS/MS assay capable of quantifying tifuvirtide in human plasma over a range of 20–10 000 ng/mL, demonstrating that pharmacokinetic monitoring is feasible in patients receiving the drug. No clinical efficacy, safety, or phase‑III trial results are presented in these abstracts, indicating that published data remain limited to early‑phase development and methodological work.
Reported Benefits
Because it blocks the earliest step of HIV infection, tifuvirtide has the theoretical advantage of retaining activity against viruses that have acquired resistance to reverse‑transcriptase or protease inhibitors. The reviews highlight its potential to act on multidrug‑resistant strains and to complement existing regimens, especially in patients who have failed standard combination therapy. The availability of a plasma assay also enables therapeutic drug monitoring, which could support individualized dosing if the drug reaches later‑stage trials.
Limitations of the Evidence
To date, tifuvirtide has not received regulatory approval and no peer‑reviewed clinical trial outcomes are reported in the cited literature. The information is limited to review articles describing its entry‑inhibitor class and an analytical method for measuring plasma concentrations. Consequently, its antiviral potency, optimal dosing, resistance profile, and safety in humans remain undefined. Without published phase‑II or phase‑III data, the practical benefit of tifuvirtide over existing agents cannot be established.
Safety Considerations
The abstracts do not provide any specific safety or adverse‑event data for tifuvirtide. As a peptide administered by injection, general cautions applicable to similar fusion inhibitors—such as injection‑site reactions, hypersensitivity, and the need for sterile technique—should be considered, but these remain speculative in the absence of published clinical experience. Until formal safety evaluations are reported, the risk profile of tifuvirtide cannot be reliably described.
How It Is Administered
Tifuvirtide is a synthetic peptide intended for parenteral delivery, most commonly subcutaneous injection, similar to the approved fusion inhibitor enfuvirtide. Formulations are expected to be supplied as sterile aqueous solutions for injection, but specific dosage forms and concentrations have not been detailed in the cited literature.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateReeves JD, Piefer AJ2005-01-01T00:00:00.000000Z
- Journal ArticleLowvan den Broek I, et al.2006-01-01T00:00:00.000000Z
- Journal ArticleLowCastagna A, et al.2005-01-01T00:00:00.000000Z
Frequently Asked Questions
What is tifuvirtide?
Tifuvirtide (T‑1249) is an investigational peptide that belongs to the class of HIV‑1 fusion inhibitors. It is being studied as a potential antiretroviral agent that blocks the virus from entering host cells.
How does tifuvirtide prevent HIV infection?
The peptide mimics a region of the viral gp41 protein and binds to its HR1 segment during the entry process. This blocks the formation of the six‑helix bundle that is required for the viral and cellular membranes to fuse.
What evidence exists for its effectiveness?
Published data are limited to review articles that list tifuvirtide as a candidate entry inhibitor and a 2006 study describing a method to measure its plasma levels. No clinical trial results, efficacy data, or safety outcomes are provided in the cited abstracts.
Is tifuvirtide approved for clinical use?
No. The abstracts do not mention regulatory approval, and the compound is described as being in early clinical‑trial development rather than as an approved medication.